TUNABLE TRANSPOSON SYSTEMS
This invention provides methods and systems for enhancement of protein production from mammalian cell lines in a drug inducible manner. The methods described herein can be used to generate a protein production cell line wherein the gene coding the protein product of interest is inserted into specific safe harbor loci (SHL) within the cell's genome and the gene copy number is induced to amplify by the use of an antibiotic inducer. The method enables for the conditional activation of the drug inducible transposase. The drug inducible gene amplification method described herein effectively functions as a molecular dial: combining drug-inducible homologous recombination and conditional gene activation to fine-tune gene amplification in mammalian systems.
1 . A system for conditional control of gene copy number amplification in an expression host cell, the system comprising:
1) a nucleic acid master regulatory construct comprising:
a transposase sequence in reverse orientation downstream from a promoter sequence, which promoter sequence is controlled by an inducing agent;
a Cre recombinase sequence with expression controlled by the inducing agent; and,
wherein the transposase sequence is upstream from a reverse oriented heterotypic first Lox sequence and downstream from a second Lox sequence, which second lox sequence is forward oriented between the promoter sequence and the transposase sequence; and,
wherein the stop sequence is bracketed by a pair of forward oriented lox sequences;
2) an expression transposon nucleic acid construct comprising:
a transposon sequence encoding a protein sequence of interest flanked by inverted terminal repeats (ITRs), which ITRs are the binding target of the transposase; and,
a binding site (BS) for the first transcriptional activator upstream from the ITRs;
wherein the presence of the inducing agent induces expression of Cre, resulting in CRE/Lox inversion of the transposase to forward orientation and resulting in excision of the stop sequence, thus resulting in expression of the transposase; enabling insertion of the transposon at particular safe harbor loci (SHL) of interest for expression of the protein of interest.
2 . The system of claim 1 , wherein the transposase is a Sleeping Beauty transposase.
3 . The system of claim 1 , further comprising one or more second transcriptional activators in the form of a ligand/receptor inducing agent.
4 . The system of claim 3 , wherein one or more of the master regulatory control construct promoter sequences is a TRE3G promoter and the inducing agent is doxycycline/reversible tetracycline transcriptional activator (Dox/rtTA).
5 . The system of claim 1 , wherein the protein of interest is an antibody heavy chain or an antibody light chain.
6 . The system of claim 1 , wherein the host cell is selected from the group consisting of: SP2/0, NS0, HEK293T, Vero, and CHO.
7 . The system of claim 1 , wherein insertion of the transposon is enabled by knock-in into one or more Safe Harbor Loci (SHL) by AAV and CRISPR enzymes Cas9, Cas12a (Cpf1), Cas12b, CasX, or CasY.
8 . The system of claim 7 , wherein the SHL is selected from the SHLs of Table 3.
9 . The system of claim 1 , wherein the master regulatory construct and expression transposon construct are on the same nucleic acid.
10 . The system of claim 1 , wherein the master regulatory construct further comprises a ubiquitous promoter controlling expression of the reversible tetracycline transcriptional activator (rtTA) and a selective pressure resistance factor (e.g., Bsd).
11 . The system of claim 10 , wherein the ubiquitous promoter is selected from the group consisting of: EF1a, CAG, Cbh, SV40, UBC, CMV, EFS, and CMV promoter combined with CMV immediate early enhancer elements.
12 . A nucleic acid master regulatory construct comprising:
a transposase sequence in reverse orientation downstream from a promoter sequence, which promoter sequence is controlled by an inducing agent;
a Cre recombinase sequence with expression controlled by the inducing agent;
wherein the transposase sequence is upstream from a reverse oriented first heterotypic Lox sequence and downstream from a second Lox sequence, which second lox sequence is forward oriented between the promoter sequence and the transposase sequence; and,
wherein the stop sequence is bracketed by a pair of forward oriented lox sequences
whereby the presence of the inducing agent induces expression of Cre, resulting in CRE/Lox inversion of the transposase to forward orientation and resulting in excision of the stop sequence, thus resulting in expression of the transposase.
13 . A method for conditional control of gene copy number amplification in an expression host cell, the method comprising:
1) providing a nucleic acid master regulatory construct comprising:
a transposase sequence in reverse orientation downstream from a promoter sequence, which promoter sequence is controlled by an inducing agent;
a Cre recombinase sequence with expression controlled by the inducing agent; and,
wherein the transposase sequence is upstream from a reverse oriented first Lox sequence and downstream from a second Lox sequence, which second lox sequence is forward oriented between the promoter sequence and the transposase sequence; and,
wherein the stop sequence is bracketed by a pair of forward oriented lox sequences;
2) providing an expression transposon nucleic acid construct comprising:
a transposon sequence encoding a protein sequence of interest flanked by inverted terminal repeats (ITRs), which ITRs are the binding target of the transposase; and,
a binding site (BS) for the first transcriptional activator upstream from the ITRs;
3) applying the inducing agent to the cell, thereby inducing expression of Cre;
4) inverting the transposase to forward orientation by a CRE/Lox inversion, thus allowing expression of the transposase;
5) inserting the transposon at one or more safe harbor loci (SHL); and,
6) expressing the protein of interest in the host cell from the one or more SHL sites.
14 . The method of claim 13 , wherein the promoter sequence is a TRE3G promoter and the inducing agent is Dox/rtTA.
15 . The method of claim 13 , further comprising controlling a copy number of inserted transposons by adjusting the concentration of the inducing agent.
16 . The method of claim 13 , further comprising selecting host cells for blasticidin (Bsd) or II puromycin (Puro) resistance.
17 . The method of claim 13 , further comprising enabling the insertion of the transposon by knock-in into the SHL by AAV and CRISPR enzymes Cas9, Cas12a (Cpf1), Cas12b, CasX, or CasY.
18 . The method of claim 13 , wherein the protein of interest is an antibody protein.
19 . The method of claim 13 , wherein the SHL is a SHL of Table 3.